BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
116.98
+2.15 (1.87%)
Apr 24, 2025, 10:28 AM EDT - Market open
BioNTech SE Revenue
In the year 2024, BioNTech SE had annual revenue of 2.75B EUR, down -27.96%. BioNTech SE had revenue of 1.19B in the quarter ending December 31, 2024, a decrease of -19.54%.
Revenue (ttm)
2.75B EUR
Revenue Growth
-27.96%
P/S Ratio
9.69
Revenue / Employee
406,246 EUR
Employees
6,772
Market Cap
28.07B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.75B | -1.07B | -27.96% |
Dec 31, 2023 | 3.82B | -13.49B | -77.94% |
Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
BNTX News
- 2 days ago - BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025 - GlobeNewsWire
- 23 days ago - Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views - Fast Company
- 23 days ago - Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul - New York Post
- 24 days ago - Vaccine stocks fall after key FDA official resigns in protest of RFK Jr. - CNBC
- 24 days ago - Biotech stocks tumble on reports FDA's top vaccine regulator to leave - Reuters
- 26 days ago - CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit - Market Watch
- 4 weeks ago - Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen - GlobeNewsWire
- 5 weeks ago - BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment - Seeking Alpha